RECRUITING

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Official Title

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Quick Facts

Study Start:2021-07-15
Study Completion:2032-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04366518

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18-65
  2. * English speaking
  3. * Right handedness
  4. * Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
  5. * History of auditory verbal hallucinations occurring at least weekly
  1. * Current substance dependence or active use as determined by drug test.
  2. * Any neurological, medical or developmental problem that is known to impair cognition significantly
  3. * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
  4. * History of seizures
  5. * History of violence
  6. * History of suicide
  7. * Pregnancy (determined by urine pregnancy test)
  8. * Concurrent participation in any other intervention study
  9. * History of urinary retention
  10. * History of delirium
  11. * Current use of any cholinergic or anticholinergic medication
  12. * History of asthma, diabetes, and cardiovascular disease
  13. * Evidence of cardiovascular disease on EKG
  14. * Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)

Contacts and Locations

Study Contact

Albert Powers, MD, PhD
CONTACT
203-974-7329
albert.powers@yale.edu
Silmilly Toribio
CONTACT
silmilly.toribio@yale.edu

Principal Investigator

Albert Powers, MD, PhD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Connecticut Mental Health Center
New Haven, Connecticut, 06519
United States

Collaborators and Investigators

Sponsor: Yale University

  • Albert Powers, MD, PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-15
Study Completion Date2032-08

Study Record Updates

Study Start Date2021-07-15
Study Completion Date2032-08

Terms related to this study

Additional Relevant MeSH Terms

  • Hallucinations, Auditory
  • Psychosis